Chapters

Transcript

Video

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Dan Atar, MD

Dan Atar, MD

Head of Research Oslo University Hospital Ulleval Professors of Cardiology University of Oslo  Oslo, Norway Visiting Associate Professorship  Johns Hopkins University Baltimore, Maryland